Merck Q2 2024: revenue $16.1B (+7% YoY); raises sales outlook but lowers EPS guidance on EyeBio charge

Merck & Co., Inc.

2024-Q2 EPS reported $4.02 revenue$31,887,000,000

Q2 revenue $16.1B (+7% YoY, +11% ex-FX); GAAP EPS $2.14, Non-GAAP EPS $2.28; KEYTRUDA sales $7.3B (+16%).
Full-year 2024 sales outlook raised to $63.4-64.4B (from $63.1-64.3B); Non-GAAP EPS guidance lowered to $7.94-8.04 (from $8.53-8.65) due to $1.3B EyeBio acquisition charge.
WINREVAIR generated $70M in Q2 sales; over 1,000 patients treated since U.S. launch in March 2024.
Completed acquisitions of EyeBio and Elanco's Aqua Business in July 2024; $0.51/share EPS impact from EyeBio.
CDC's ACIP unanimously recommended CAPVAXIVE; positive EU CHMP opinion for WINREVAIR in PAH.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.